The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: New Treatments and Strategies Emerge for Osteoporosis

ACR/ARHP Annual Meeting 2012: New Treatments and Strategies Emerge for Osteoporosis

January 1, 2013 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Colored scanning electron micrograph (SEM) of an osteoporotic femur head. In places, the surface of the bone has been eroded to reveal the underlying tissue.

WASHINGTON, D.C.—Using bisphosphonates to prevent the loss of bone mass associated with rheumatic conditions can require a deft touch—and even some guesswork—because it is unclear how long they should be used. The longer they’re used, the more likely it is they might cause harm, an expert said during a session titled, “Osteoporosis: From Bisphosphonates and Beyond,” here at the 2012 ACR/ARHP Annual Meeting, held November 9–14. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis
Explore This Issue
January 2013
Also By This Author
  • Effectiveness of Novel Therapies for Cutaneous SLE Explored

This is an area that calls for caution, Chad Deal, MD, head of the Center for Osteoporosis and Metabolic Bone Disease at the Cleveland Clinic, said during the session about the latest in treatment for, and management of, osteoporosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“It’s pretty clear from the data that these atypical [femur] fractures are increased with increasing use,” Dr. Deal said. One study found that the number of atypical femur fractures stood at 113 per 100,000 patients per year at about the eighth year of taking the drugs.1

According to two prominent studies on the topic, the number of patients you need to treat to prevent a hip fracture is 91, and the number needed to treat to prevent a radiographic vertebral fracture is 14. The number needed to harm with an atypical femur fracture is 417.1,2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“For each atypical fracture caused, at least 30 vertebral and five hip fractures are prevented,” Dr. Deal said.

When to Stop Bisphosphonates

The U.S. Food and Drug Administration (FDA) has been vague when it comes to how long bisphosphonates should be used, but suggests there might be no advantage in continuing treatment after five years.

The evidence, though, shows there might be benefit to taking the drugs longer. For instance, people taking alendronate longer than five years showed more lumbar spine bone mineral density improvements after the fifth year than those who switched to placebo at five years.3

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One study by Dieb and Watts that has been submitted for publication suggests grouping patients into mild, moderate, and high-risk fracture categories based on their history of fracture, clinical risk factors, and fracture risk scores (T scores and FRAX), with the higher risk groups getting longer duration of treatment.

Other Drugs to Prevent Bone Loss

Nelson Watts, MD, director of the Mercy Health Osteoporosis and Bone Health Services in Cincinnati, said that denosumab, a receptor activator of nuclear factor κB ligand (RANKL)–inhibitor approved in 2010 for women with postmenopausal osteoporosis who are at high risk of fracture, performs well.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: ACR/ARHP Annual Meeting, bisphosphonates, bone loss, Osteoporosis, TreatmentIssue: January 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis
  • 2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.